Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Net Margin (2018 - 2025)

Ligand Pharmaceuticals' Net Margin history spans 15 years, with the latest figure at 75.06% for Q4 2025.

  • For Q4 2025, Net Margin rose 14767.0% year-over-year to 75.06%; the TTM value through Dec 2025 reached 46.42%, up 6502.0%, while the annual FY2025 figure was 46.42%, 4884.0% up from the prior year.
  • Net Margin for Q4 2025 was 75.06% at Ligand Pharmaceuticals, down from 101.57% in the prior quarter.
  • Across five years, Net Margin topped out at 101.57% in Q3 2025 and bottomed at 93.64% in Q1 2025.
  • The 5-year median for Net Margin is 6.99% (2021), against an average of 5.04%.
  • The largest annual shift saw Net Margin crashed -6057bps in 2021 before it skyrocketed 14767bps in 2025.
  • A 5-year view of Net Margin shows it stood at 3.94% in 2021, then crashed by -49bps to 5.86% in 2022, then surged by 35bps to 3.79% in 2023, then tumbled by -1818bps to 72.62% in 2024, then surged by 203bps to 75.06% in 2025.
  • Per Business Quant, the three most recent readings for LGND's Net Margin are 75.06% (Q4 2025), 101.57% (Q3 2025), and 10.18% (Q2 2025).